| Dr Linda Lazarus Benjamin, MD | |
|
50 Lakefront Blvd, Buffalo, NY 14202-4327 | |
| (716) 849-8750 | |
| (716) 849-8756 |
| Full Name | Dr Linda Lazarus Benjamin |
|---|---|
| Gender | Female |
| Speciality | General Practice |
| Location | 50 Lakefront Blvd, Buffalo, New York |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780691840 | NPI | - | NPPES |
| 00722514 | Medicaid | NY | |
| 6409370 | Other | NY | IHA |
| 00010014301 | Other | NY | UNIVERA |
| 005085852 | Other | NY | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 135545 (New York) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Linda Lazarus Benjamin, MD 50 Lakefront Blvd, Buffalo, NY 14202-4327 Ph: (716) 849-8750 | Dr Linda Lazarus Benjamin, MD 50 Lakefront Blvd, Buffalo, NY 14202-4327 Ph: (716) 849-8750 |
News Archive
Scientists seeking new ways to fight maladies ranging from arthritis and osteoporosis to broken bones that won't heal have cleared a formidable hurdle, pinpointing and controlling a key molecular player to keep stem cells in a sort of extended infancy.
Lazarus Effect, a medical device company focused on the development of novel interventional devices to facilitate removal of blood clots, announced the closing of a $5 million financing. Proceeds from the financing will support EU commercialization of several approved Lazarus Effect devices, as well as regulatory filings for the Lazarus ReCover and Lazarus Cover in the United States.
CNN examines the work of a Harvard University chemistry professor to "shrink a medical laboratory onto a piece of paper that's the size of a fingerprint and costs about a penny." According to George Whitesides, who created a prototype of the inexpensive paper "chip," the technology could be used to diagnose such diseases as HIV, malaria and tuberculosis in developing countries.
Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for Jevtana® (cabazitaxel) Injection in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-containing treatment regimen.
ChromaDex Corp., an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a joint collaboration agreement with St. Jude Children's Research Hospital to evaluate ChromaDex's natural product libraries.
› Verified 3 days ago
Mrs. Michele Lea Bassler, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 126 W Humboldt Pkwy, Buffalo, NY 14214 Phone: 716-829-9410 | |
Qamar Zaman Khan, DO General Practice Medicare: Not Enrolled in Medicare Practice Location: 462 Grider St, Buffalo, NY 14215 Phone: 716-898-3941 | |
Armida Orozco, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 219 Brynt St, Woman & Children Hosp Of Buffalo, Buffalo, NY 14207 Phone: 716-878-7777 Fax: 716-888-3802 | |
Dr. Robert James Duve, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 462 Grider St, Buffalo, NY 14215 Phone: 716-898-3941 |